You made all your effort to warn people regarding the recent surge in Vaccine related stocks. Which is good. But too much of an effort looks like a sour grape to me. No hard feelings.
DickyMe , emil, NPRA1985, Thanks for your kind reminder towards those who bought this share. But sorry. We see the potential in it and have decided to move higher. Win or lose has nothing to do with you. Those who curse about limit down, you will have the same in your stock portfolio. Like i said, fengshui turn around, karma goes around.
Like glove counters last time,some cursed them down but they went up sky-high faster than you and me could imagine.you don't seem to learn your lesson.we go with the theme or you will regret at your loss of opportunities.....
Chinese vaccine company CanSino Biologics, one of the frontrunners for a COVID-19 vaccine, is slated to conclude phase III trials of its vaccine candidate Ad5-nCoV in January 2022.
The Chinese company CanSino Biologics developed a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences. In May, they published promising results from a Phase 1 safety trial, and in July they reported that their Phase 2 trials demonstrated the vaccine produced a strong immune response. In an unprecedented move, the Chinese military approved the vaccine on June 25 for a year as a “specially needed drug.” CanSino would not say whether vaccination would be mandatory or optional for soldiers. Starting in August, CanSino began running Phase 3 trials in a number of countries, including Saudi Arabia, Pakistan and Russia.
@drteh84 Face it. Sinopharm vaccine is way ahead of Cansino vaccine in phase 3 and higher chance of being the one supplied to Malaysia based on the vaccine agreement with China. Sinopharm is state owned whereas Cansino is private. Safety profile of inactivated vaccines is proven. Safety profile of Adenovirus vector vaccine is questionable.
@drteh84 Either way I will not be a loser. My attachment with this stock is still intact since 2014. And I have been buying intermittently since the days it lay low under 10 sen.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
drteh84
527 posts
Posted by drteh84 > 2020-11-30 00:02 | Report Abuse
You made all your effort to warn people regarding the recent surge in Vaccine related stocks. Which is good. But too much of an effort looks like a sour grape to me. No hard feelings.